The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
Lynn Foster
Advertisement
Senior Partner, Leadership Advisory, WittKieffer
Articles by Lynn Foster
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
4
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
5
